• Dehydroepiandrosterone (DHEA) Research Workflows

  2026-09-13

  Dehydroepiandrosterone (DHEA) supports two distinct research strategies: endocrine challenge modeling in ovarian biology and concentration-controlled studies of neural survival. This practical guide connects formulation, assay design, and troubleshooting with the mitochondrial steroidogenesis findings reported in a recent PCOS study.

• Prednisone as a Translational Immunology Benchmark

  2026-09-12

  Prednisone offers translational researchers a defined synthetic corticosteroid benchmark for studying lymphocyte cell-cycle control, IL-2 signaling, apoptosis, formulation variables, and the limits of connecting immune assays with neurodegeneration models.

• BV6: Reframing IAP Antagonism for Translation

  2026-09-11

  BV6 is a Smac-mimetic IAP antagonist that provides a mechanistically tractable way to study apoptosis, treatment sensitization, and disease-model biology. This thought-leadership analysis connects IAP-dependent survival signaling with RIPK3–MLKL pathway resolution, offering translational researchers a strategy for stronger experimental design without overstating preclinical evidence.

• Cefepime (BMY-28142) in CNS Infection Models

  2026-09-11

  Explore how Cefepime (BMY-28142) can support central nervous system infection research through mechanism-informed antibacterial, barrier-transport, and neurotoxicity assays. This guide translates cephalosporin PK/PD principles into practical experimental decisions without conflating cefepime with newer comparator antibiotics.

• Plerixafor (AMD3100): Assay Reliability Guide

  2026-09-10

  A scenario-based guide to using Plerixafor (AMD3100), SKU A2025, in CXCR4 signaling, migration, viability, and mobilization studies. It connects formulation, controls, quantitative potency data, and interpretation strategies to help laboratories reduce assay ambiguity and improve experimental comparability.

• Mitoxantrone Workflows for ABCG2 Resistance

  2026-09-10

  Build reproducible Mitoxantrone assays for DNA-damage response, apoptosis, and transporter-mediated drug resistance. This guide connects controlled DMSO handling with ABCG2 accumulation studies and marein combination experiments, while separating oncology applications from early anti-orthopoxvirus research.

• Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO)

  2026-09-09

  Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) helps limit endogenous proteolysis during protein extraction and sample preparation without introducing EDTA into cation-sensitive workflows. It is appropriate for applications such as Western blotting, co-immunoprecipitation, pull-down assays, phosphorylation analysis, and kinase assays, but it should not be treated as a substitute for metalloprotease or phosphatase inhibition when those activities must be controlled.

• SP600125 for Nanoplastic Vascular Signaling

  2026-09-09

  Explore how SP600125, a selective JNK inhibitor, can test whether JNK contributes to nanoplastic-induced vascular lipid dysregulation beyond the established ERK/UHRF1 axis. This evidence-aware workflow connects developmental cardiovascular toxicology with rigorous pathway-dissection strategies.

• Astrocytic GAT-3 Controls Dentate Gyrus Memory

  2026-09-08

  The reference study shows that astrocytic GAT-3 is an active signaling mechanism in the entorhinal cortex–dentate gyrus circuit, not merely a transporter that clears GABA. By linking GAT-3-dependent astrocyte calcium signaling to presynaptic GluN2B-containing NMDARs and contextual fear memory, it provides a mechanistic framework for studying glia-mediated synaptic plasticity.

• Ademetionine in Neurological Disorders: Evidence and Limits

  2026-09-08

  Bottiglieri, Hyland, and Reynolds presented an integrative review linking central nervous system methylation, folate and vitamin B12 metabolism, monoamine signaling, and neurological disease. Its practical value lies in showing why ademetionine may be relevant across depression, dementia, demyelinating disease, and metabolic disorders while emphasizing that the clinical evidence was preliminary and heterogeneous.

• Everolimus (RAD001): From Arrest to Cell Death

  2026-09-07

  Everolimus (RAD001) is an mTOR pathway inhibitor whose apparent viability effects can reflect growth arrest, cell killing, or both. This guide applies a time-resolved framework to improve cancer assay interpretation and translational relevance.

• Aminopeptidase Selectivity and ACE Inhibitor Action

  2026-09-07

  The 1992 study directly compared metallopeptidase inhibitors against cell-surface aminopeptidases A, N, and W, revealing that inhibitor behavior differed substantially across closely related enzymes. Its findings caution against inferring aminopeptidase selectivity from ACE inhibitor activity alone and provide a framework for designing more discriminating biochemical assays.

• Astrocytic GAT-3 in Dentate Gyrus Memory

  2026-09-05

  The reference study identifies astrocytic GAT-3 as an active signaling component in the entorhinal cortex–dentate gyrus circuit, rather than only a GABA clearance transporter. Its electrophysiological, optogenetic, calcium, and behavioral evidence connects GAT-3 activity to astrocytic Ca2+ signaling, presynaptic GluN2B-containing NMDA receptors, enhanced excitatory transmission, and contextual fear-memory formation.

• HIV-1, Nuclear Pores, and Resting T Cells

  2026-09-04

  The reference study identifies nuclear pore complex remodeling as a major bottleneck limiting HIV-1 infection of resting CD4+ T cells. It shows that cell–cell spread activates CD4–LCK–CDK1 signaling, phosphorylates nucleoporins without requiring cell-cycle entry, and enables viral capsid nuclear import.

• Cell Integrity Limits Ploidy in Budding Yeast

  2026-09-04

  The reference study defines a physiological ceiling for genome amplification in budding yeast and links that ceiling to cell size and surface stress rather than chromosome content alone. Its experimental framework provides a useful basis for interpreting membrane-integrity phenotypes, while also showing why drug-related conclusions require separate validation.

8526 records 1/569 page Next 12345 下5页 Last page